SCHEMBL3596283

SCHEMBL3596283

O=C(Cn1cc2ccccc2n1)NCCNCC1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 1/20 0.44
BACE1 P56817 1/20 0.43
CNR1 P21554 1/20 0.42
EPHX2 P34913 1/20 0.42
TSHR P16473 3/20 0.41
KDM4E B2RXH2 2/20 0.41
POLB P06746 1/20 0.41
ALOX15 P16050 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NPC1 O15118 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
RAB9A P51151 2/20 0.40
METTL3 Q86U44 1/20 0.40
ADRB1 P08588 1/20 0.39
ADRB3 P13945 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3596281 0.80 ACHE (0.47) BACE1TSHRPOLBHPGDSMN1; SMN2
SCHEMBL3598193 0.76 LMNA (0.57) HDAC6TSHRALDH1A1SMN1; SMN2MEN1
SCHEMBL3589932 0.76 LMNA (0.47) HDAC6BACE1TSHRKDM4EPOLB
SCHEMBL3600244 0.76 GAA (0.58) KDM4EPOLBALOX15ALDH1A1HSD17B10
SCHEMBL3602594 0.76 TSHR (0.57) EPHX2TSHRPOLBALOX15ALDH1A1
SCHEMBL3595022 0.75 HSD17B10 (0.55) EPHX2TSHRKDM4EALOX15ALDH1A1
SCHEMBL3608186 0.74 KDM4E (0.54) HDAC6TSHRKDM4EALDH1A1HSD17B10
SCHEMBL3587773 0.74 ALDH1A1 (0.50) HDAC6KDM4EPOLBALDH1A1SMN1; SMN2
SCHEMBL3596889 0.74 HTT (0.66) HDAC6ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3595689 0.74 ALDH1A1 (0.51) HDAC6TSHRKDM4EPOLBALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 HDAC6 1799/4885BACE1 3253/4885CNR1 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.